Cover Image

Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial (ROBOT-2 trial)

Background: For patients with esophageal adenocarcinoma or cancer of the gastroesophageal junction, radical esophagectomy with 2-field lymphadenectomy is the cornerstone of the multimodality treatment with curative intent. Both conventional minimally invasive esophagectomy (MIE) and robot assisted m...

Full description

Saved in:
Bibliographic Details
Main Authors: Tagkalos, Evangelos (Author) , van der Sluis, P. C. (Author) , Berlth, Felix (Author) , Poplawski, A. (Author) , Hadzijusufovic, E. (Author) , Lang, H. (Author) , van Berge Henegouwen, M. I. (Author) , Gisbertz, S. S. (Author) , Müller, Beat P. (Author) , Ruurda, J. P. (Author) , Schiesser, M. (Author) , Schneider, P. M. (Author) , van Hillegersberg, R. (Author) , Grimminger, P. P. (Author)
Format: Article (Journal)
Language:English
Published: 26 September 2021
In: BMC cancer
Year: 2021, Volume: 21, Pages: 1-12
ISSN:1471-2407
DOI:10.1186/s12885-021-08780-x
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-021-08780-x
Verlag, lizenzpflichtig, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08780-x
Get full text
Author Notes:E. Tagkalos, P.C. van der Sluis, F. Berlth, A. Poplawski, E. Hadzijusufovic, H. Lang, M.I. van Berge Henegouwen, S.S. Gisbertz, B.P. Müller-Stich, J.P. Ruurda, M. Schiesser, P.M. Schneider, R. van Hillegersberg and P.P. Grimminger
Description
Summary:Background: For patients with esophageal adenocarcinoma or cancer of the gastroesophageal junction, radical esophagectomy with 2-field lymphadenectomy is the cornerstone of the multimodality treatment with curative intent. Both conventional minimally invasive esophagectomy (MIE) and robot assisted minimally invasive esophagectomy (RAMIE) were shown to be superior compared to open transthoracic esophagectomy considering postoperative complications. However, no randomized comparison exists between MIE and RAMIE in the Western World for patients with esophageal adenocarcinoma. Methods: This is an investigator-initiated and investigator-driven multicenter randomized controlled parallel-group superiority trial. All adult patients (age ≥ 18 and ≤ 90 years) with histologically proven, surgically resectable (cT1-4a, N0-3, M0) esophageal adenocarcinoma of the intrathoracic esophagus or adenocarcinoma of the gastroesophageal junction and with European Clinical Oncology Group performance status 0, 1 or 2 will be assessed for eligibility and included after obtaining informed consent. Patients (n = 218) with resectable esophageal adenocarcinoma of the intrathoracic esophagus or adenocarcinoma of the gastroesophageal junction are randomized to either RAMIE (n = 109) or MIE (n = 109). The primary outcome of this study is the total number of resected abdominal and mediastinal lymph nodes specified per lymph node station.
Item Description:Published online: 26 September 2021
Gesehen am 09.03.2022
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-021-08780-x

Similar Items